Biopharmaceutical therapy for treatment of Primary Hyperoxaluria


The use of naturally occurring bacteria from the human gut as pharmaceutical drugs has gained increased interest, as knowledge about the human microbiota and its role in health and disease has advanced considerably with new technology and computational techniques.
The primary aim of the ELIMOX project is to develop an innovative and unique bacterial pharmaceutical product for the treatment of a severe and debilitating inherited disease, Primary Hyperoxaluria (PH).

  • Status
  • Completed
  • Project Launch
  • 01 October 2013
  • Project completed
  • 30 September 2015
Primary Hyperoxaluria human micro-biota bacterial product

Project Website